黄花夹竹桃甙(thevetoside,TS)属强心甙类药,1.5 mg·kg~(-1)·d~(-1)ip治疗小鼠腹水瘤H22,EAC,P388及实体瘤S180,U14,Lewis肺癌,仅对实体瘤有效,抑瘤率为48.7％—56.7％。TS与轻度抑瘤作用剂量(0.3,0.5或1.0 mg·kg~(-1)·d~(-1))的氮芥合用,抑瘤活性高于单独给药组,能使腹水瘤小鼠的生存期延长率达到82.4至>122.1％;对实体瘤的抑瘤率为65.6％—72.5％ Thevetoside (TS) is a kind of cardiotonic drug, 1.5 mg·kg -1 ·d -1 ip treatment of mouse ascites tumor H22, EAC, P388 and solid tumor S180, U14 Lewis lung cancer is only effective for solid tumors, and the tumor inhibition rate is 48.7%-56.7%. The combination of TS with mild anti-tumor effect dose (0.3, 0.5 or 1.0 mg·kg -1 ·d -1) of nitrogen mustard had higher anti-tumor activity than that of the single administration group, which could make the ascites tumor smaller. The survival rate of mice increased from 82.4 to >122.1%; the rate of inhibition of solid tumors was 65.6% to 72.5%